文献速递呼吸衰竭与机械通气儿科与产科急症

高频振荡通气与常频机械通气治疗婴儿重症呼吸道合胞病毒肺炎:一项随机对照试验

[High frequency oscillatory ventilation and conventional mechanical ventilation in the treatment of infants with severe respiratory syncytial virus pneumonia: a randomized controlled trial].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2021-01-01
一句话结论婴儿重症RSV肺炎机械通气时,HFOV较CMV更早改善氧合和生理指标,减少心率下降、SpO2下降和CPR,但增加肌松剂使用和7天液体正平衡,未增加气胸、颅内出血等严重并发症。

该研究为前瞻性随机对照试验,纳入2018年1月至2019年12月首都儿科研究所附属儿童医院ICU收治的28例需有创机械通气的重症RSV肺炎婴儿,按入院顺序以随机数字表分为HFOV组13例和CMV组15例。入组6小时,HFOV组心率、呼吸频率、SpO2下降例数、心率下降例数、CPR例数及氧合指数(OI)均显著低于CMV组(均P<0.05),而肌松剂使用例数和7天液体正平衡量显著高于CMV组。两组均无血液净化治疗、无气胸和颅内出血等严重并发症、28天内无死亡。结论提示HFOV可更早改善氧合和临床生理指标、减少不良事件,临床应用安全。

要点

  • 入组6小时HFOV组OI为6.5(4.4, 8.9) vs CMV组9.3(8.0, 12.8),HFOV组显著降低(P<0.05)。
  • 入组6小时HFOV组HR 130(125, 138)bpm vs CMV组144(140, 160)bpm,HFOV组显著降低(P<0.05)。
  • 入组6小时SpO2下降1例 vs 10例、心率下降0例 vs 6例、CPR 0例 vs 4例,HFOV组均显著减少(均P<0.05)。
  • HFOV组肌松剂使用3例 vs CMV组0例、7天液体正平衡167.1(113.8, 212.6)mL/kg vs 90.8(57.8, 112.7)mL/kg,HFOV组显著更高(均P<0.05)。
  • 两组均无气胸、颅内出血等严重并发症,均未行血液净化,28天内均无死亡。

适用人群与场景

  • 2018年1月至2019年12月首都儿科研究所附属儿童医院ICU收治的需有创机械通气的重症RSV肺炎婴儿。

处置流程与药物剂量

  • 按入院顺序以随机数字表将患儿分为HFOV组或CMV组。

研究设计与关键结果

  • 研究类型为前瞻性随机对照试验,共纳入28例婴儿,CMV组15例、HFOV组13例。
  • 两组入组前年龄、体重、小儿危重评分、OI、II型呼吸衰竭、多器官功能障碍、基础疾病及实验室检查指标均无显著差异。
  • 入组6小时,HFOV组较CMV组HR 130(125, 138)bpm vs 144(140, 160)bpm、RR 35(34, 38)次/min vs 40(35, 45)次/min、SpO2下降1例 vs 10例、心率下降0例 vs 6例、CPR 0例 vs 4例、OI 6.5(4.4, 8.9) vs 9.3(8.0, 12.8)均显著降低(均P<0.05)。
  • 入组6小时,HFOV组肌松剂使用3例 vs CMV组0例、7天液体正平衡167.1(113.8, 212.6)mL/kg vs 90.8(57.8, 112.7)mL/kg,HFOV组显著更高(均P<0.05)。
  • 两组均无血液净化治疗,无气胸、颅内出血等严重并发症,28天内无死亡。

证据类型、等级与局限

  • 证据类型:前瞻性随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,与CMV相比,HFOV治疗婴儿重症RSV肺炎可更早改善氧合水平和临床生理指标,减少HR、SpO2下降和CPR等不良事件的发生率,增加肌松剂使用和液体正平衡,不增加气胸、颅内出血等严重并发症的发生率,临床应用安全。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To compare the clinical efficacy of high frequency oscillatory ventilation (HFOV) and conventional mechanical ventilation (CMV) in the treatment of infants with severe respiratory syncytial virus (RSV) pneumonia.

METHODS: A prospective randomized controlled trial was conducted. The infants with severe RSV pneumonia who received invasive mechanical ventilation admitted to intensive care unit (ICU) of Children's Hospital Affiliated to Capital Institute of Pediatrics from January 2018 to December 2019 were enrolled. According to the order of admission, each infant was assigned to HFOV group or CMV group by random number table. The basic data, pediatric critical score, blood gas analysis, ventilator parameters, oxygenation index [OI, OI = mean airway pressure (Pmean)×fraction of inspired oxygen (FiO2)/arterial partial pressure of oxygen (PaO2)×100], duration of mechanical ventilation, length of ICU stay, complications, prognosis, use of muscle relaxants and vasoactive drugs and other clinical indicators of the two groups were recorded.

RESULTS: A total of 28 infants were enrolled in the analysis, including 15 infants receiving CMV and 13 infants receiving HFOV. There were no significant differences in age, body weight, pediatric critical score and OI before enrollment, type II respiratory failure, multiple organ dysfunction, basic diseases and laboratory examination indexes before enrollment between the two groups. Six hours after enrollment, compared with CMV group, heart rate (HR), respiratory rate (RR), case of transcutaneous oxygen saturation (SpO2) decrease, case of HR decrease, case of cardiopulmonary resuscitation (CPR) and OI in HFOV group were significantly decreased [HR (bpm): 130 (125, 138) vs. 144 (140, 160), RR (times/min): 35 (34, 38) vs. 40 (35, 45), SpO2 decrease (case: 1 vs. 10), HR decrease (case: 0 vs. 6), CPR (case: 0 vs. 4), OI: 6.5 (4.4, 8.9) vs. 9.3 (8.0, 12.8)], while case of use of muscle relaxants (case: 3 vs. 0) and volume of 7-day positive fluid balance [mL/kg: 167.1 (113.8, 212.6) vs. 90.8 (57.8, 112.7)] were significantly higher, the differences were statistically significant (all P < 0.05). There was no use of blood purification treatment, no severe complications such as pneumothorax and intracranial hemorrhage, and no death within 28 days in the two groups.

CONCLUSIONS: Compared with CMV, HFOV in the treatment of infants with severe RSV pneumonia can improve the oxygenation level and clinical physiological indexes earlier, reduce the incidence of adverse events such as HR, SpO2 decrease and CPR, increase the use of muscle relaxants and the positive fluid balance, and do not increase the incidence of severe complications such as pneumothorax and intracranial hemorrhage, so its clinical application is safe.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Zhang J, Qu D, Ren X, et al. [High frequency oscillatory ventilation and conventional mechanical ventilation in the treatment of infants with severe respiratory syncytial virus pneumonia: a randomized controlled trial]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021. PMID: 34053490. doi:10.3760/cma.j.cn121430-20201106-00706

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。